Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Interim phase I/IIa results for Genta's G-3139 as non-Hodgkin's lymphoma agent

July 12, 1996

Canji issued two patents for p53 gene therapy for cancer

July 12, 1996

Arizona Board of Regents reports antitumor pentapeptides

July 12, 1996

Potent tyrosine kinase inhibitors derived from PD-089828

July 12, 1996

Protein farnesyltransferase inhibitor in Warner-Lambert's compound library

July 12, 1996

PD-158780: A potent and selective EGF tyrosine kinase inhibitor

July 12, 1996

Protein tyrosine kinase inhibitors from Warner-Lambert

July 12, 1996

Arimidex approved for Austrian, German and Italian markets

July 12, 1996

Taxotere approved in eight countries for two indications

July 12, 1996

Yoshitomi and Yamasa Shoyu out-license DMDC

July 12, 1996

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 13, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...